Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of RO4917838 for persistent predominantly negative symptoms in schizophrenia
CTR20131504Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bitopertin in schizophrenia, sponsored by Roche. Started Jan 2015; status: active.
02
Drugs
bitopertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20131504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131504.